ADMET検査(吸収/分布/代謝/排泄/毒性検査)の世界市場:インビトロADMET検査、インビボADMET検査、インシリコADMET検査...市場調査レポートについてご紹介

【英文タイトル】Pharma ADMET Testing: World Industry and Market Prospects 2015-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of the World Market for ADMET Testing
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. An Introduction to ADMET Testing
2.1 What Is ADMET Testing?
2.1.1 Absorption
2.1.2 Distribution
2.1.3 Metabolism
2.1.3.1 MIST Guidelines
2.1.4 Excretion
2.1.5 Toxicology
2.2 The Role of ADMET Testing in Biosimilarity
2.3 Trial Design and Execution
2.3.1 Phases of Drug Development
2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
2.3.1.2 Phase I Trials: First-In-Human Studies
2.3.1.3 Phase II Trials: Proof-Of-Concept
2.3.1.4 Phase III Trials: Preparing for Approval Applications
2.3.1.5 Post-Marketing Studies
2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
2.3.3 Benefits of Outsourcing

3. ADMET Testing: World Market 2015-2025
3.1 Pharma R&D Expenditures by Phase, 2014
3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
3.1.2 Big Pharma Companies Are the Leading Clients for CROs
3.2 The ADMET Testing Market 2015-2025
3.2.1 What Will Drive Growth in ADMET Testing 2015-2025?
3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2025

4. ADMET Testing: Revenue by Segment 2015-2025
4.1 Which Market Sector Will Account for the Most Revenue from 2015-2025?
4.2 Rising Demand for Predictive ADMET Testing throughout the Decade
4.3 In Vitro ADMET Testing Market
4.3.1 In Vitro ADMET Testing: Drivers and Restraints
4.4 In Vivo ADMET Testing Market
4.4.1 In Vivo ADMET Testing: Drivers and Restraints
4.5 In Silico ADMET Testing
4.5.1 In Silico ADMET Testing: Drivers and Restraints

5. ADMET Testing: Leading Developed Markets 2015-2025
5.1 Leading National Markets for ADMET Testing 2014
5.2 ADMET Testing: Leading National Market Forecasts 2015-2025
5.3 North America as a Destination for Drug Development
5.3.1 The US: The Largest National Market for ADMET Testing 2015-2025
5.3.1.1 Government Programs to Improve ADMET in the US
5.3.2 The US: ADMET Testing Revenue Forecast 2015-2025
5.4 The Outlook for ADMET Testing in the EU5 2015-2025
5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025
5.4.3 Germany: Market Forecast 2015-2025
5.4.4 The UK
5.4.4.1 Overcoming Challenges in UK Clinical Trials
5.4.4.2 UK ADMET Testing Market Forecast 2015-2025
5.4.5 France: Market Forecast 2015-2025
5.4.6 Italy: Market Forecast 2015-2025
5.4.7 Spain: Market Forecast 2015-2025
5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
5.5.1 Growth for ADMET Testing in Japan 2015-2025

6. ADMET: Leading Emerging Markets 2015-2025
6.1 Leading Emerging Markets for ADMET Testing 2014
6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2025
6.3 ADMET in Asia Pacific: An Emerging Market Perspective
6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
6.3.1.1 CRO Investments and Partnerships in China
6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2025
6.3.2 India as a Hub for Clinical Trials
6.3.2.1 Indian ADMET Testing Market Forecast 2015-2025
6.3.3 South Korea
6.3.3.1 Promoting Local Drug Development in South Korea
6.3.3.2 Growth in the South Korean ADMET Market 2015-2025
6.4 Russia
6.4.1 Changing Drug Development Demands 2010-2015
6.4.2 Russian ADMET Market Forecast 2015-2025
6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2025
6.5.1 Brazilian ADMET Testing Market Forecast 2015-2025

7. Leading Companies in the ADMET Testing Industry 2014
7.1 Agilent Technologies, Inc.
7.1.1 Agilent Technologies, Inc.: Historical Revenues 2011-2014
7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
7.2.1 Accelrys: Historical Revenues 2011-2013
7.3 Cyprotex
7.3.1 Cyprotex Acquires CeeTox
7.3.2 Cyprotex Historical Revenues, 2010-2014
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2011-2014
7.5 Quintiles
7.5.1 Expanding in Developed and Emerging Markets
7.6 Increasing Asian Regional Reach
7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
7.8 WuXi PharmaTech
7.8.1 WuXi Acquires XenoBiotic Laboratories
7.8.2 WuXi Enters the Clinical Trial Services Market
7.9 Promega Corporation
7.10 Merck KGaA’s Acquisition of Sigma Aldrich

8. ADMET Testing Market: Industry Trends 2015-2025
8.1 Strengths and Weaknesses of the ADMET Testing Market
8.2 Opportunities and Threats in the ADMET Testing Market
8.3 ADMET Testing Market: STEP Analysis 2015-2025
8.3.1 Social Factors Affecting ADMET 2015-2025
8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
8.5 Economic Considerations for ADMET Testing 2015-2025
8.5.1 Demand for Predictive ADMET Testing
8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2025
8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
8.6.2 Strategic Partnering for Long Term Revenue Growth
8.6.2.1 Sharing Risk Between Pharma and CROs
8.6.3 A Note on CRO Selection
8.6.3.1 Small Pharmaceutical Companies and CROs
8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

9. Research Interviews
9.1 Interview with Dr Roustem Saiakhov, President of MultiCASE, Inc.
9.1.1 Addressing the Challenges in ADMET Testing
9.1.2 Trends in the ADMET Testing Market
9.2 Interview with Yong Huang, PhD, President and CEO of Optivia Biotechnology
9.2.1 ADMET Services at Optivia Biotechnology
9.2.2 Optivia’s Partnership with Rhenovia Pharma: CNS Drug Development
9.2.3 Optivia’s Partnership with Hurel Corporation: In Vitro-to-In Vivo Correlation
9.2.4 Challenges and Trends in Drug Discovery
9.2.5 Growth of Optivia Biotechnology in the Future?
9.3 Interview with Kristina Runeberg, Site Head of Takara Bio Europe AB
9.3.1 Acquisition of Cellectis AB
9.3.2 Addressing the Challenges in ADMET Testing
9.3.3 Trends in the ADMET Testing Market

10. Conclusions from Our Study
10.1 The World ADMET Testing Market in 2014
10.1.1 A Market Dominated by the Developed Countries
10.2 Strong Growth for the Overall Market 2015-2025
10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
10.3.1 How Can CROs Specialise to Remain Competitive?


【レポート販売概要】

■ タイトル:ADMET検査(吸収/分布/代謝/排泄/毒性検査)の世界市場:インビトロADMET検査、インビボADMET検査、インシリコADMET検査
■ 英文:Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
■ 発行日:2015年10月
■ 調査会社:visiongain
■ 商品コード:VGAIN5102611
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。